Back to Journals » Therapeutics and Clinical Risk Management » Volume 13

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab

Authors Hanley TL, Yiu ZZN

Received 2 December 2016

Accepted for publication 27 January 2017

Published 13 March 2017 Volume 2017:13 Pages 315—323

DOI https://doi.org/10.2147/TCRM.S111107

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh

Tessa L Hanley,1 Zenas ZN Yiu2,3

1Fairfield General Hospital, Bury, 2Centre for Dermatology, 3Centre for Pharmacoepidemiology and Drug Safety, Manchester Academic Health Science Centre, Manchester, UK

Abstract: Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine or associated receptors. Ixekizumab is a subcutaneously administered humanized monoclonal antibody, which acts to neutralize IL-17A. This article reviews the role of IL-17 in the pathogenesis of psoriasis, the biological and pharmacokinetics of ixekizumab and the safety profile and the clinical efficacy of ixekizumab in Phase III clinical trials. Phase III clinical trials of ixekizumab have so far demonstrated excellent early clinical efficacy, with a comparable safety profile to the existing biologic therapies for psoriasis. To further assess its position in the treatment algorithm for psoriasis, a further head to head RCT with secukinumab could be established, alongside comparative effectiveness studies from observational research. In addition, trials are needed to assess its role in those with tumor necrosis factor inhibitors/ustekinumab resistant disease. However, it is clear that the IL-17 antagonists have changed the benchmark for clinical efficacy, and it is likely that ixekizumab along with the other IL-17 antagonists are set to achieve a new standard of care in the treatment of moderate to severe plaque psoriasis.

Keywords: interleukin-17, psoriasis, IL-17, ixekizumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Hanley T, Handford M, Lavery D, Yiu ZZN

Psoriasis: Targets and Therapy 2016, 6:41-54

Published Date: 1 April 2016